Tempest Therapeutics

Tempest possesses a well-balanced and extensive pipeline comprising innovative and top-notch small molecule treatments, which influence specific pathways relevant to triggering an efficient anti-cancer response. Tempest has formed a skilled team of small molecule and immuno-oncology drug researchers to progress these initiatives to the medical trial stage across various types of cancer that present substantial unmet healthcare requirements. Tempest is supported by a consortium of prominent venture capital firms based in the US and China.